PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Overview of attention for article published in OncoTargets and therapy, January 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#25 of 2,967)
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 15,077 followers.

RT @fghton: $tgtx Novaritis out there as well.... Interesting article to read... https://t.co/cQ7nptBxKb

RT @fghton: $tgtx Novaritis out there as well.... Interesting article to read... https://t.co/cQ7nptBxKb

$tgtx Novaritis out there as well.... Interesting article to read... https://t.co/cQ7nptBxKb

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design - Dove Medical Press https://t.co/3FZQQbBco2